Overview

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Phase:

Phase 1

Details

Lead Sponsor:

Medical University of South Carolina

Treatments:

Aspirin
Clopidogrel
Pembrolizumab